Validation of New Biomarkers for Monitoring Plasmodium falciparum Reduced susceptibility/Tolerance or Resistance to Artemisinin Derivatives and Partner Drugs in Nigeria
TA.2007.40200.016
EDCTP1
Senior Fellowship (SF)
1. Evaluate clinical treatment response parameters, in vitro and in vivo efficacy and drug blood levels of artemether-lumefantrine (AL) and artesunate-amodiaquine (AS-AQ) combinations in patients’ infected with P. falciparum in Ibadan, Southwest Nigeria 2. Use the PCR, DNA sequencing approaches to identify new biomarkers/ molecular determinants of P. falciparum response to ARTs and Partner drugs in vitro and in vivo 3. Validate the role of new biomarkers/molecular determinants of P. falciparum response to ARTs and partner drugs by collating SNPs/SNPs patterns in parasite genes with clinical treatment response parameters, patients’ treatment outcome, blood drug levels and in vitro quantitative responses (phenotypes).
In vitro and in vivo bio-markers studies
Department | Institution | Country |
---|---|---|
University of Ibadan | Nigeria |